Survivor average causal effects for continuous time : a principal stratification approach to causal inference with semicompeting risks
License
Access Rights
Cadmus Permanent Link
Full-text via DOI
ISBN
ISSN
0323-3847; 1521-4036
Issue Date
Type of Publication
LC Subject Heading
Other Topic(s)
EUI Research Cluster(s)
Initial version
Published version
Succeeding version
Preceding version
Published version part
Earlier different version
Initial format
Citation
Biometrical journal, 2025, Vol. 67, No. 2, Art. e70041, OnlineFirst
Cite
COMMENT, Leah, MEALLI, Fabrizia, HANEUSE, Sebastien, ZIGLER, Corwin M., Survivor average causal effects for continuous time : a principal stratification approach to causal inference with semicompeting risks, Biometrical journal, 2025, Vol. 67, No. 2, Art. e70041, OnlineFirst - https://hdl.handle.net/1814/78186
Abstract
In semicompeting risks problems, nonterminal time-to-event outcomes, such as time to hospital readmission, are subject to truncation by death. These settings are often modeled with illness-death models for the hazards of the terminal and nonterminal events, but evaluating causal treatment effects with hazard models is problematic due to conditioning on survival—a posttreatment outcome—that is embedded in the definition of a hazard. Extending an existing survivor average causal effect (SACE) estimand, we frame the evaluation of treatment effects in the context of semicompeting risks with principal stratification and introduce two new causal estimands: the time-varying survivor average causal effect (TV-SACE) and the restricted mean survivor average causal effect (RM-SACE). These principal causal effects are defined among units that would survive regardless of assigned treatment. We adopt a Bayesian estimation procedure that parameterizes illness-death models for both treatment arms. We outline a frailty specification that can accommodate within-person correlation between nonterminal and terminal event times, and we discuss potential avenues for adding model flexibility. The method is demonstrated in the context of hospital readmission among late-stage pancreatic cancer patients.
Table of Contents
Additional Information
Published online: 06 March 2025